Researchers estimate the number of people globally living with chronic obstructive pulmonary disease (COPD) will hit 600 million by 2050. There are certain risk factors for COPD, including obesity and ...

The Centers for Medicare & Medicaid Services announced Nov. 25 that Medicare recipients will pay less for 15 prescription ...

For patients with chronic obstructive pulmonary disease (COPD), the Global Initiative on Obstructive Lung Disease recommends long-term term pharmacologic and nonpharmacologic therapies based on each ...

The therapies combine three proven medicines-Glycopyrronium, Formoterol, and Budesonide-to reduce airway obstruction, control ...

In 2024, drugmakers delivered breakthrough treatments in conditions that had seen little progress for decades—and helped make existing therapies more accessible. Approved in July, Eli Lilly’s Kisunla ...

The U.S. Food and Drug Administration on Tuesday approved the first generic Symbicort drug used to treat asthma and chronic obstructive pulmonary disease (COPD), which are two common pulmonary health ...

A study found that opioid use, with or without benzodiazepines, significantly increases long-term mortality risk in patients with chronic obstructive pulmonary disease (COPD) over the age of 60 years.

The Trump administration late Tuesday announced new lower Medicare prices for 15 drugs that were part of the latest round of ...

The Medicare health plan said on Tuesday that newly negotiated prices for 15 of its costliest drugs will save 36% on those ...

SNS Insider Reports Steady Growth of the U.S. Asthma and COPD Drugs Market from USD 8.56 Billion in 2025E to USD 12.68 Billion by 2033, Supported by Awareness Programs, Expanding Biologic Usage, and ...